The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain



Status:Completed
Conditions:Cancer, Cancer, Chronic Pain, Pain
Therapuetic Areas:Musculoskeletal, Oncology
Healthy:No
Age Range:21 - Any
Updated:5/5/2014
Start Date:February 2011
End Date:June 2015
Contact:Isabel Arcos, MS
Email:isabela@aemf.org
Phone:661-702-6729

Use our guide to learn which trials are right for you!

THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN

• The objectives of this study are to confirm the medication delivery accuracy of the
Infusion System, LLC Implantable Drug Delivery System (IDDS) with Patient Controlled
Analgesia for intrathecal delivery of morphine sulfate for pain control, and to determine
the safety profile of the system with PCA for intrathecal delivery of morphine sulfate for
pain control.


Inclusion Criteria:

1. Subject must be at least 21 years of age.

2. Subject must have experienced chronic pain for at least 6 months.

3. Subject must not presently be on intrathecal therapy but must be considered a
candidate for intrathecal analgesia by his pain specialist; or, a subject already on
intrathecal therapy must be in need of a replacement intrathecal pump and catheter.

4. Subject must be capable of giving informed consent.

5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting
narcotic prescriptions to the study physician.

6. Subjects who agree to periodic drug testing.

7. Subject must be capable and willing to follow all study-related procedures, including
returning for monthly refills.

8. Subject must be cognitively intact and, in the opinion of the Investigator, capable
of using the Patient Remote.

9. Subject who is not already successfully treated with intrathecal analgesic therapy
must be responsive to a trial of intrathecal or epidural morphine.

10. Female subjects of child-bearing potential must agree to use a medically acceptable
and effective double-barrier method of birth control.

11. Documented failure to respond to less invasive methods of pain control (such as
physical or behavioral modifications).

12. Ineffective pain control with single or multiple systemic analgesic treatments (oral,
rectal, IV or transdermal) or had intolerable side effects.

13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog
Scale (VAS) score of greater than or equal to 4/10.

14. Subjects who can receive an MRI.

15. Subjects must be able to hear and respond to audible alarms or agree to have a
support person available who is able to hear and respond to audible alarms.

Exclusion Criteria:

1. Subject is a female who is pregnant or is planning a pregnancy.

2. Subject is a nursing mother.

3. Subject has at the site chosen for implantation a skin condition that would prevent
the implantation procedure.

4. Subject has participated in an investigational drug or device trial within 4 weeks
prior to enrollment.

5. Subject has any known or suspected allergy to morphine or to the materials of the
infusion pump or intrathecal catheter.

6. Subject shows signs of active, systemic infection.

7. Subject has a known central nervous system contraindication to intrathecal therapy,
including but not limited to severe spinal canal stenosis or spinal cord compression.

8. Subject has a body size that is insufficient to accept the bulk and weight of the
pump.

9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is
contraindicated.

10. Subject has a condition requiring diathermy procedures.

11. Subject has a life expectancy of less than 9 months.

12. Subject cannot independently comprehend and participate in the required assessments,
including responding to the QOL, BPI, ODI and PGIC measurement tools.

13. Subject is not considered to be medically or psychologically appropriate for pump
implantation.

14. Subject has a urine drug screen result which indicates the use of prescription drugs
or controlled substances not on the order of a physician.

15. Subjects with an ASA Physical Status >IV.

16. Subjects with a history of spinal instability, or grade II spondylolisthesis or
greater.

17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to
the implantation procedures.

18. Subjects who are unable or unwilling to return to all of the required follow-up
visits.

19. Subjects who are unwilling to sign the informed consent.

20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or
electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians,
MRI engineers and MRI clinicians).

21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear
implants and neurostimulators or other medical device use that can interfere with the
function of the implanted intrathecal pump.
We found this trial at
9
sites
Napa, California 94558
?
mi
from
Napa, CA
Click here to add this to my saved trials
Bloomington, Illinois 61701
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Carlsbad, California 92009
?
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Eugene, Oregon 97401
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Evansville, Indiana 47714
?
mi
from
Evansville, IN
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Scottsdale, Arizona 85258
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
St. Louis, Missouri 63109
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials